VERA logo

VERA Vera Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$27.54
-0.56 (-1.98%)

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat…

Market Cap: $1.99Bveratx.com

Price

No data yet.

Social Signal Score

53
5d
—
30d
50
3 mentions
—
60d
57
7 mentions
—
90d
53
12 mentions
—
news: 12

Analyst Ratings

14 analysts
Buyconsensus
Strong Buy 1Buy 12Hold 1Sell 0Strong Sell 0
Avg price target$77+179.6%
Low $29Median $76.5High $125
Current Consensus

Revenue

$10.28M
$0.00$3.43M$6.85M$10.28M
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-4.58
$-4.85–$-4.42
9 analysts
FY2026
$-5.90
$-6.50–$-5.58
9 analysts
FY2027
$-3.71
$-5.02–$-2.21
9 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Marshall Fordyce
Sector
Healthcare
Industry
Biotechnology
Employees
362
Beta
0.95
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
4.06
veratx.com